Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 34 (6), 421-8

Clinical Pharmacokinetics of Lornoxicam. A Short Half-Life Oxicam

Affiliations
Review

Clinical Pharmacokinetics of Lornoxicam. A Short Half-Life Oxicam

N M Skjodt et al. Clin Pharmacokinet.

Abstract

Lornoxican (chlorotenoxicam) is a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class. Unlike other oxicams, lornoxicam has a relatively short plasma half-life (3 to 5 hours). Lornoxicam is eliminated following biotransformation to 5'-hydroxy-lornoxicam, which does not undergo enterohepatic recirculation. Glucoroconjugated metabolites are excreted in urine and faeces with a half-life of about 11 hours. Lornoxicam and its metabolites bind extensively to plasma albumin. Substantial concentrations of lornoxicam are attained in synovial fluid, the proposed site of action in chronic inflammatory arthropathies. The effects of lornoxicam concentration on its therapeutic and toxicological properties have not yet been extensively reported. Lornoxicam, like other NSAIDs, appears to interact with warfarin, sulphonylureas, digoxin and furosemide.

Similar articles

See all similar articles

Cited by 11 PubMed Central articles

See all "Cited by" articles

References

    1. J Chromatogr. 1993 Jul 23;617(1):105-10 - PubMed
    1. Postgrad Med J. 1988 Oct;64(756):752-4 - PubMed
    1. Postgrad Med J. 1993 Nov;69(817):865-6 - PubMed
    1. Int J Tissue React. 1993;15(3):125-34 - PubMed
    1. Postgrad Med J. 1990;66 Suppl 4:S28-9 - PubMed

Publication types

MeSH terms

LinkOut - more resources

Feedback